Comparative Pharmacology
Head-to-head clinical analysis: DEPAKOTE CP versus PROMPT PHENYTOIN SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEPAKOTE CP versus PROMPT PHENYTOIN SODIUM.
DEPAKOTE CP vs PROMPT PHENYTOIN SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Valproate increases GABA concentration in the brain by inhibiting GABA transaminase and succinic semialdehyde dehydrogenase. It also blocks voltage-gated sodium channels and T-type calcium channels.
Phenytoin stabilizes neuronal membranes by promoting sodium channel inactivation, thereby reducing repetitive firing of action potentials and inhibiting the spread of seizure activity.
250-500 mg orally twice daily, titrated by 250 mg/day every 3-7 days; maximum 60 mg/kg/day. Target trough serum concentration: 50-100 mcg/mL.
Loading dose: 15-20 mg/kg (max 1500 mg) IV at a rate not exceeding 50 mg/min. Maintenance dose: 300-600 mg/day IV or orally in 3 divided doses. Adjust per therapeutic drug monitoring (target total phenytoin 10-20 mcg/mL).
None Documented
None Documented
Terminal elimination half-life is 9-16 hours (mean ~12 hours) in adults; prolonged in hepatic impairment, elderly, and neonates.
30-100 hours (average 40 hours) following IV administration; prolonged in hepatic impairment, neonates, and with enzyme inhibitors; shorter in children and with enzyme inducers.
Renal: 30-50% as glucuronide conjugates, 3% as unchanged drug; fecal: minimal; less than 3% excreted in bile.
Primarily hepatic metabolism (CYP2C9) to inactive p-HPPH. Renal excretion as p-HPPH glucuronide (~60-70%) and unchanged drug (5%), with ~30% biliary/fecal elimination.
Category C
Category D/X
Anticonvulsant
Anticonvulsant